Another study, PALOMA-2, was a phase III, double-blind, randomised (2:1) clinical trial which included 666 postmenopausal women with advanced breast cancer, positive estrogen receptors, and HER-2 negative who had not received any prior treatment. Here, ERBB2 is linked to breast carcinoma.